Lyell Immunopharma, Inc. - 8-K Filing
Lyell Immunopharma reports Q3 2026 net loss of $45.5 million and announces $80.0 million private placement. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $LYEL
Read the full article at SEC EDGAR
Part of the story IDEAYA Biosciences, Inc. - 8-K Filing (42 articles)